#ESC22: Bay­er's chron­ic kid­ney dis­ease drug miss­es the mark on low­er­ing car­dio­vas­cu­lar death

BARCELONA — It’s been a rough two days for Bay­er at the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy Con­gress. Just af­ter re­port­ing dis­ap­point­ing re­sults for the fac­tor XIa in­hibitor asun­dex­i­an, the Big Phar­ma said its ap­proved med Keren­dia al­so didn’t reach sig­nif­i­cance on all-cause mor­tal­i­ty in a pooled analy­sis of two Phase III tri­als of the drug.

The drug was ap­proved by the FDA last Ju­ly to slow chron­ic kid­ney dis­ease pro­gres­sion in pa­tients with CKD as­so­ci­at­ed with type 2 di­a­betes. The Eu­ro­pean Med­i­cines Agency fol­lowed up with its nod in Feb­ru­ary 2022, Japan’s health min­istry in March and Chi­na’s med­ical prod­ucts agency in June.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER